Trials / Completed
CompletedNCT01623895
Pharmacogenetic Study in Patients Received Iron Chelating Agent
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.
Detailed description
Transfusion-associated iron overload induces systemic toxicity. Recently, deferasirox, a convenient long acting oral agent, has been introduced in clinical practice with promising efficacy. However, some patients experience drug-related toxicities and cannot tolerate it. To investigate effect of genetic variations on the toxicities and find optimal target population, we planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase 1A (UGT1A) subfamily, multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) among pediatric patients received deferasirox.
Conditions
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-06-20
- Last updated
- 2014-07-14
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01623895. Inclusion in this directory is not an endorsement.